FOLH1 and hepatocellular carcinoma: This fact indicates that 68Ga PSMA PET/CT imaging may play a role in the assessment of treatment response and the selection of those patients with hepatocellular carcinoma who may benefit from non-PSMA-targeting antiangiogenic treatment strategies.